Status:
COMPLETED
Study Evaluating Etanercept in Moderate to Severe Asthma
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.
Eligibility Criteria
Inclusion
- Moderate to severe persistent asthma for at least 1 year
- Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted
- Subjects must be on a high-dose inhaled corticosteroid (ICS)
Exclusion
- Previous treatment with etanercept
- Current use of cigarettes
- Significant concurrent medical conditions at the time of screening
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00141791
Start Date
May 1 2005
End Date
July 1 2006
Last Update
August 7 2009
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35209
2
Denver, Colorado, United States, 80206
3
Sarasota, Florida, United States, 34233
4
Tallahassee, Florida, United States, 32308